Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.40

Mkt cap

5.7M

Volume

41K

High

1.40

P/E Ratio

-1.14

52-wk high

6.80

Low

1.36

Div yield

N/A

52-wk low

0.92

Clearmind Medicine has entered into an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement is for the development of Generation 3.0 psychedelic compounds aimed at treating mental disorders.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 11:50 am

Clearmind Medicine has filed a patent application with the USPTO for a psychedelic-based treatment targeting eating disorders. This move could potentially open new therapeutic avenues and markets for the company, emphasizing its commitment to innovating in the mental health treatment space.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 11:20 am

Clearmind Medicine's CEO has released a letter to shareholders, expressing optimism about achieving significant milestones through 2024, which are expected to substantially enhance shareholder value.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:09 pm

The article provides a comprehensive roundup of recent developments in the psychedelics sector, highlighting research findings, regulatory updates, and industry movements. Key highlights include the launch of Usona Institute's Phase 3 clinical trial on psilocybin for Major Depressive Disorder, partnerships for psilocybin research, and significant corporate changes within companies like Compass Pathways and Cybin. Additionally, several companies announced progress in clinical trials, patent approvals, and expansions in product distribution.

Portfolio Pulse from Lara Goldstein

March 30, 2024 | 12:57 pm

Beckley Psytech and atai Life Sciences announced positive results from a Phase 2a study of 5-MeO-DMT for Treatment Resistant Depression. Utah hospitals will soon offer psilocybin and MDMA therapy. Elon Musk discussed the benefits of ketamine for depression and its positive impact on investors. Meta is under investigation for potentially facilitating illegal drug sales. MindMed's CEO highlighted LSD's potential in a podcast. Various companies and ETFs are mentioned with their stock performance.

Portfolio Pulse from Lara Goldstein

March 29, 2024 | 4:43 pm

SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) have advanced their collaboration with a new international patent application for a treatment aimed at preventing and treating depression. This application involves a novel composition combining Clearmind's MEAI compound with SciSparc's CannAmide™. The global market for depression and anxiety disorders treatment is projected to grow significantly, indicating a substantial market opportunity for this collaboration.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:56 pm

Cybin Inc. received FDA Breakthrough Therapy designation for its psilocybin therapy for Major Depressive Disorder, alongside positive clinical data and a $150M private placement. MindMed also received the designation for its LSD-derived treatment for Generalized Anxiety Disorder, with expected proceeds of $175M from share offerings. Gilgamesh Pharmaceuticals was awarded a $14M grant for ibogaine analog research. Psyence Biomedical, Red Light Holland, and Clearmind Medicine were mentioned for their developments in psychedelics. The article also covered stock performances of several psychedelics companies.

Portfolio Pulse from Lara Goldstein

March 20, 2024 | 6:49 pm

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares surged 27.1% in pre-market trading after reporting a significant year-over-year decrease in FY23 losses and providing positive clinical updates. Other stocks also showed notable pre-market movements, with several companies experiencing significant gains or losses due to various factors such as financial results, business updates, and public offerings.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 12:20 pm

Clearmind Medicine's stock is trading higher following the announcement of divisional patent approval by the China National Intellectual Property Administration.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:59 am

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced receiving divisional patent approval in China from the China National Intellectual Property Administration for its treatments.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:56 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.